Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
